Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag™ (Nanodisc-pro)

ユーザーレビュー
製品番号/仕様
価格
数量
CD0-H82D3-20ug
$1020.00
CD0-H82D3-100ug
$1820.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Nanodisc-pro Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (CD0-H82D3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a Flag tag at the N-terminus and a polyhistidine tag at the C-terminus followed by an Avi tag (Avitag™). The protein has a calculated MW of 39.1 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H8113) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc-pro membrane protein is wrapped by a piece of cell membrane and scaffold, the info of scaffold can be found in above red text "isotope type control...".

    2. Synthesis Process

      Nanodisc-pro membrane protein extraction is a gentle, non-disruptive process that directly isolates full-length transmembrane proteins together with their surrounding native phospholipids from cellular membranes, without breaking or disturbing the original membrane structure. This preserves the membrane protein's natural conformational landscape and native lipid environment, yielding stable nanodisc that retain cellular phospholipids, with fully preserved biological activity—making them ideal for cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA), etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.6-39 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Ofatumumab biosimilar with a linear range of 0.001-0.078 μg/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Obinutuzumab biosimilar with a linear range of 0.03-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     CD20 SPR

    Biotinylated Human CD20 Full Length Protein, Flag Tag&His,Avitag (Cat. No. CD0-H82D3) immobilized on SA Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 240 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     CD20 FACS

    2e5 of Anti-CD20 CAR-293 cells were stained with 100 μL of 3 μg/mL Biotinylated Human CD20 Full Length Protein, FlagTag&His,Avitag (Cat. No. CD0-H82D3) and negative control protein respectively, washed and then followed by PE-SA and analyzedwith FACS (QC tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    B-lymphocyte antigen CD20

  • カテゴリ:

  • 市販の医薬品数:

    35 詳細

  • 治験医薬品数:

    132 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8